EN DE
STOCK COMPARISON

Yifan Xinfu Pharmaceutical Co vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Yifan Xinfu Pharmaceutical Co (002019) and Eli Lilly and (LLY) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Yifan Xinfu Pharmaceutical Co as the less overvalued of the two: Yifan Xinfu Pharmaceutical Co trades at ¥10.34 versus a fair value of ¥6.89 (-33%), while Eli Lilly and trades at $1,186 versus $397 (-67%).
Yifan Xinfu Pharmaceutical Co
002019.SHE · CNY · Health Care
-33%
upside to fair value
overvalued
Price¥10.34
Fair Value¥6.89
Quality56/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,186
Fair Value$397
Quality69/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Yifan Xinfu Pharmaceutical CoEli Lilly and
Valuation
34.4×P/E (TTM)42.2×
2.40×P/S (TTM)14.67×
1.37×P/B39.94×
16.5×EV/EBITDA30.2×
0.35×PEG1.54×
1.0%Dividend yield0.5%
¥0.10Dividend per share$6.23
Profitability
7%Net margin35%
12%Operating margin49%
4%Return on equity107%
2%Return on assets21%
Growth
-5%Revenue growth (YoY)56%
10.2%Avg. growth/yr (3Y)31.7%
-1.0%Avg. growth/yr (5Y)21.6%
Balance & size
0.10×Debt / equity1.54×
$2BMarket cap$1.1T
weakGrowth qualitymixed

Even match: 7 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Yifan Xinfu Pharmaceutical Coof which business quality 54 · market factors 31 Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
31
85
Quality GrowthAre margins and returns improving?
54
86
CashflowEarnings quality: real cash, not paper profit
23
51
Fin. StrengthBalance sheet, leverage, solvency risk
70
53
InvestmentDisciplined investing over empire-building
82
15
Low VolatilityCalm price path (market factor)
75
73
MomentumPrice trend over the last 3–12 months (market factor)
15
78
52W MomentumDistance to the 52-week high (market factor)
8
92
Net IssuanceBuybacks instead of dilution
85
93

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Yifan Xinfu Pharmaceutical Co

DCF Models¥3.88
Earnings-Based¥4.51
Multiples¥6.67
Asset-Based¥4.87
Economic Profit¥5.05
Growth Earnings¥6.89

13 of 15 models see the stock below the current price.

Eli Lilly and

DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Yifan Xinfu Pharmaceutical Co
Bear ¥4.96Fair Value ¥6.89Bull ¥8.95
¥10.34 = current price (white tick)
Eli Lilly and
Bear $222Fair Value $397Bull $582
$1,186 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Yifan Xinfu Pharmaceutical Co · Health Care

Quality score56 · above median
Fair value upside-33% · below median

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-67% · bottom 25%

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Yifan Xinfu Pharmaceutical Co as the less overvalued of the two: Yifan Xinfu Pharmaceutical Co trades at ¥10.34 versus a fair value of ¥6.89 (-33%), while Eli Lilly and trades at $1,186 versus $397 (-67%).

Eli Lilly and has the higher quality score (69/100).

See the full analysis →
Yifan Xinfu Pharmaceutical Co · Eli Lilly and

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Yifan Xinfu Pharmaceutical Co

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Eli Lilly and

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.